From Local Support to Global Policy: Expanding Our Impact
In November 2023, the ADHD Foundation submitted a formal request to the U.S. Drug Enforcement Administration (DEA) to raise production quotas for a long-acting ADHD medication. The motivation was clear: tackle worsening international shortages and ensure patients worldwide receive the treatment they depend on.
DEA Production Quota: What Changed and Why It Matters
Originally, the DEA intended to maintain its 2024 production quota at 2023 levels. However, after active advocacy by the ADHD Foundation and other global stakeholders, the DEA announced a 24% increase in September 2024—75% of which was designated for international distribution.
“The ADHD Foundation submission was directly cited by the DEA. This increase acknowledges the growing international need for equitable ADHD treatment access.”
Advocacy Recognition: Australian Voices Lead Change
In its official update, the DEA credited the advocacy efforts of Australian organisations, particularly the ADHD Foundation, for raising global awareness of supply shortfalls. Our submission played a decisive role in reversing the DEA’s initial stance.
Prescription Surge in Australia: A Data-Driven Concern
Internal analysis of Department of Health data revealed that prescriptions for this specific treatment in Australia increased by over 350% between 2019–20 and 2022–23. This significant rise in demand placed further pressure on already limited global supplies.
Limited Access: The Patent Barrier in Australia
Although a generic version of the medication became available in the U.S. in 2023, the treatment remains under active patent in Australia. This restricts treatment options and exacerbates shortages for Australian patients.
What It Means for Australians Living with ADHD
While previous DEA quotas weren’t the direct cause of Australian shortages, global caps clearly impacted international availability. The new U.S. quota revision marks a pivotal step toward realigning supply with surging worldwide demand.
Direct from the Source: Statement from the Manufacturer
“We appreciate the ADHD Foundation’s advocacy in support of this quota increase. Submissions from Australia were cited in the DEA’s final notice and played a key role in shaping their decision. Supply distribution details are still pending, but we’ll provide updates as they become available.”
Our Ongoing Mission: Support, Equity, and Awareness
Despite being a volunteer-run, non-government funded organisation, the ADHD Foundation continues to:
- Operate Australia’s free national ADHD helpline
- Deliver evidence-based community services
- Advocate for equitable treatment access across borders
- Monitor medicine availability trends and share timely updates